AXA Private Equity, a European diversified private equity firm, has acquired Riemser Arzneimittel, an international specialty pharmaceutical company headquartered in Greifswald, Germany.
AXA Private Equity has acquired the shareholdings of Riemser’s founding Braun family and those of various minority stakeholders, including TVM Capital. The completion of the transaction remains subject to approval by the German competition authority.
Riemser operates internationally and has a primary focus on the sales, marketing and lifecycle management of pharmaceutical products for niche therapeutic markets with high medical need in the fields of oncology, anti-infectives and dermatology. In 2011, Riemser, which has around 500 employees on its payroll, posted sales revenues of approximately EUR100m.
Christof Naményi, managing director of AXA Private Equity, said: "Riemser Arzneimittel is characterised by an increasing strategic focus on specialist niche therapeutic markets and is successfully pursuing an international growth strategy. With our global network, we will be actively supporting the strategy of continued specialisation and internationalisation which has been pursued by our management."
Michael Mehler, chief executive of Riemser, says: "We are delighted to have found in AXA Private Equity a strong partner with whom we can continue our growth strategy systematically. The measures adopted over the past few years – such as internationalisation and the increased specialisation and strengthening of our product portfolio in selected therapeutic areas – have been the right steps on our path towards a successful future."
